» Articles » PMID: 19563448

Calcitonin and Carcinoembryonic Antigen Doubling Times As Prognostic Factors in Medullary Thyroid Carcinoma: a Structured Meta-analysis

Overview
Specialty Endocrinology
Date 2009 Jul 1
PMID 19563448
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Context: In the management of patients with medullary thyroid carcinoma (MTC), calcitonin doubling time (dt) has gained interest as an independent predictor of recurrence and survival.

Objective: To perform a structured meta-analysis of the diagnostic value of calcitonin dt, carcinoembryonic antigen (CEA) dt and the combination and to define dt strata with the highest predictive power. Design The study was a meta-analysis using individual data.

Methods: Ten studies containing data on the post-operative kinetics of tumour marker(s) and (recurrence free) survival were included.

Results: Calcitonin- and CEA-dt are significant indicators for survival (hazard ratios (HR) 21.52 respectively infinite for dt 0-1 year compared to dt >1 year) and recurrence (HR 5.33 respectively 6.80 for dt 0-1 year compared to dt >1 year). The highest predictive power was found for the dt classification 0-1 year vs. >1 year. CEA dt has a higher predictive value than calcitonin dt in the subgroup of patients for which both parameters were available.

Conclusion: The dts of both calcitonin and CEA are strong prognostic indicators for MTC recurrence and death. CEA dt has a higher predictive value than calcitonin dt and therefore measuring both tumour markers is essential for proper risk stratification.

Citing Articles

Validation of the International Medullary Thyroid Cancer Grading System and Identification of EZH2 as a Prognostic and Potential Therapeutic Marker in Medullary Thyroid Cancer.

Jager E, van Hemel B, Rutgers B, Zandee W, Jansen L, Kruijff S Cancers (Basel). 2025; 17(5).

PMID: 40075585 PMC: 11899120. DOI: 10.3390/cancers17050737.


Time Kinetics and prognosis roles of calcitonin after surgery for medullary thyroid carcinoma.

Guo F, Fu G, Li F, Hua Y, Wang Z, Zheng X World J Surg Oncol. 2024; 22(1):121.

PMID: 38711029 PMC: 11071271. DOI: 10.1186/s12957-024-03397-3.


Spontaneous and Treatment-Related Changes of Serum Calcitonin in Medullary Thyroid Cancer: Long-Term Experience in a Patient With Multiple Endocrine Neoplasia Type 2B.

Reti Z, Tabak A, Garami M, Kalina I, Kiss G, Sapi Z JCO Precis Oncol. 2024; 8:e2300675.

PMID: 38709988 PMC: 11161236. DOI: 10.1200/PO.23.00675.


Changes of biochemical factors and the effect on recurrence of medullary thyroid carcinoma after surgery.

Guo F, Li L, Gu P, Zhang G, Ruan X, Zhao J Heliyon. 2024; 10(8):e29857.

PMID: 38681571 PMC: 11046226. DOI: 10.1016/j.heliyon.2024.e29857.


Serum Biochemical Markers for Medullary Thyroid Carcinoma: An Update.

Liu S, Zhao H, Li X Cancer Manag Res. 2024; 16:299-310.

PMID: 38617188 PMC: 11011642. DOI: 10.2147/CMAR.S440477.